Cited In for PMID: 19737969

Year	Number of Results
2009	1
2010	8
2011	8
2012	16
2013	15
2014	16
2015	17
2016	11
2017	12
2018	11
2019	10
2020	7
2021	12
2022	11
2023	6
2024	1

1

Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.

Lin E, Li L, Guan Y, Soriano R, Rivers CS, Mohan S, Pandita A, Tang J, Modrusan Z. Lin E, et al. Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737969

2

Discovery of novel anaplastic lymphoma kinase (ALK) and histone deacetylase (HDAC) dual inhibitors exhibiting antiproliferative activity against non-small cell lung cancer.

Wang KL, Yeh TY, Hsu PC, Wong TH, Liu JR, Chern JW, Lin MH, Yu CW. Wang KL, et al. J Enzyme Inhib Med Chem. 2024 Dec;39(1):2318645. doi: 10.1080/14756366.2024.2318645. Epub 2024 Mar 11. J Enzyme Inhib Med Chem. 2024. PMID: 38465731 Free PMC article.

3

ALK fusions in the pan-cancer setting: another tumor-agnostic target?

Shreenivas A, Janku F, Gouda MA, Chen HZ, George B, Kato S, Kurzrock R. Shreenivas A, et al. NPJ Precis Oncol. 2023 Sep 29;7(1):101. doi: 10.1038/s41698-023-00449-x. NPJ Precis Oncol. 2023. PMID: 37773318 Free PMC article. Review.

4

DAB2IP suppresses invadopodia formation through destabilizing ALK by interacting with USP10 in breast cancer.

Huang Q, Zhang R, Xia Y, Shen J, Dong H, Li X, Tao D, Xie D, Liu L. Huang Q, et al. iScience. 2023 Aug 11;26(9):107606. doi: 10.1016/j.isci.2023.107606. eCollection 2023 Sep 15. iScience. 2023. PMID: 37664607 Free PMC article.

5

Patient-led advocacy in ALK-positive lung cancer.

Barton C, Al Achkar M, Blender JA, Farmen SH, Hall RB, Konidari AM, Martinez D, Pronsati N, Rosenzweig M, Vass C, Venanzi ES, Westlake W, Muskavitch MAT. Barton C, et al. Transl Lung Cancer Res. 2023 Jun 30;12(6):1303-1319. doi: 10.21037/tlcr-22-713. Epub 2023 Jun 29. Transl Lung Cancer Res. 2023. PMID: 37425399 Free PMC article. Review.

6

New perspectives for targeting therapy in ALK-positive human cancers.

Zhao S, Li J, Xia Q, Liu K, Dong Z. Zhao S, et al. Oncogene. 2023 Jun;42(24):1959-1969. doi: 10.1038/s41388-023-02712-8. Epub 2023 May 6. Oncogene. 2023. PMID: 37149665 Review.

7

Molecular Anatomy of the EML4-ALK Fusion Protein for the Development of Novel Anticancer Drugs.

Cheon SY, Kwon S. Cheon SY, et al. Int J Mol Sci. 2023 Mar 18;24(6):5821. doi: 10.3390/ijms24065821. Int J Mol Sci. 2023. PMID: 36982897 Free PMC article. Review.

8

Exceptional response to alectinib for duodenal carcinoma with ALK fusion: A case report and literature review.

Isaka Y, Sasaki A, Saito A, Motomura Y, Ando Y, Nakamura Y. Isaka Y, et al. Front Oncol. 2023 Jan 12;12:1064944. doi: 10.3389/fonc.2022.1064944. eCollection 2022. Front Oncol. 2023. PMID: 36713517 Free PMC article.

9

Current status and challenges of immunotherapy in ALK rearranged NSCLC.

Qi R, Yu Y, Shen M, Lv D, He S. Qi R, et al. Front Oncol. 2022 Dec 14;12:1016869. doi: 10.3389/fonc.2022.1016869. eCollection 2022. Front Oncol. 2022. PMID: 36591504 Free PMC article.

10

Comprehensive assessment of anaplastic lymphoma kinase in localized and metastatic prostate cancer reveals targetable alterations.

Patel RA, Coleman I, Roudier MP, Konnick EQ, Hanratty B, Dumpit R, Lucas JM, Ang LS, Low JY, Tretiakova MS, Ha G, Lee JK, True LD, De Marzo AM, Nelson PS, Morrissey C, Pritchard CC, Haffner MC. Patel RA, et al. Cancer Res Commun. 2022 May;2(5):277-285. doi: 10.1158/2767-9764.crc-21-0156. Epub 2022 May 2. Cancer Res Commun. 2022. PMID: 36337169 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

151 results

Results by year